Last reviewed · How we verify
NCT02857920
Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors
Completed
Phase 1, PHASE2
Last updated 14 September 2020
What this trial tests
Phase 1, PHASE2 trial testing Bevacizumab in Malignant Solid Tumour in 45 participants. Completed in 1 August 2019.
Timeline
1 August 2016
Primary endpoint
1 August 2017
1 August 2017
1 August 2019
Quick facts
| Lead sponsor | Fuda Cancer Hospital, Guangzhou |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 45 |
| Start date | 1 August 2016 |
| Primary completion | 1 August 2017 |
| Estimated completion | 1 August 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
- NK immunotherapy — full drug profile →
Conditions studied
- Malignant Solid Tumour — all drugs for Malignant Solid Tumour →
Sponsor
Fuda Cancer Hospital, Guangzhou
Who can join
Adults 18 to 75, any sex, with Malignant Solid Tumour. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is the safety and efficacy of Bevacizumab plus allogeneic natural killer (NK) immunotherapy to many kinds of recurrent solid tumors.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
Fukumura D, Kloepper J, Amoozgar Z, Duda DG, et al · · 2018 · cited 1560× · PMID 29508855 · DOI 10.1038/nrclinonc.2018.29 -
Targeting Tumor Microenvironment for Cancer Therapy.
Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. · · 2019 · cited 865× · PMID 30781344 · DOI 10.3390/ijms20040840 -
NK cell-based cancer immunotherapy: from basic biology to clinical development.
Liu S, Galat V, Galat Y, Lee YKA, et al · · 2021 · cited 504× · PMID 33407739 · DOI 10.1186/s13045-020-01014-w -
Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors.
Melaiu O, Lucarini V, Cifaldi L, Fruci D. · · 2019 · cited 324× · PMID 32038612 · DOI 10.3389/fimmu.2019.03038 -
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.
Lamers-Kok N, Panella D, Georgoudaki AM, Liu H, et al · · 2022 · cited 125× · PMID 36348457 · DOI 10.1186/s13045-022-01382-5 -
Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy.
Choi Y, Jung K. · · 2023 · cited 100× · PMID 37907742 · DOI 10.1038/s12276-023-01114-w -
Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.
Joshi S, Sharabi A. · · 2022 · cited 85× · PMID 35122833 · DOI 10.1016/j.pharmthera.2022.108114 -
Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges.
Li SJ, Chen JX, Sun ZJ. · · 2021 · cited 63× · PMID 34137513 · DOI 10.1002/cac2.12183
Verify or expand the search:
- PubMed search for NCT02857920
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Bevacizumab
Trials testing the same drug.
- NCT07504588 — Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and · Phase 2 · not yet recruiting
- NCT07500298 — Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable · Phase 1 · not yet recruiting
- NCT07271355 — Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colore · Phase 3 · not yet recruiting
- NCT07318389 — ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer · EARLY_PHASE1 · not yet recruiting
- NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
Other recruiting trials for Malignant Solid Tumour
Currently open trials in the same condition.
- NCT07044336 — Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) · Phase 3 · recruiting
Other Fuda Cancer Hospital, Guangzhou trials
Trials by the same sponsor.
- NCT04393220 — Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma · Phase 2 · completed
- NCT03673137 — Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC · Phase 2, PHASE3 · completed
- NCT03976206 — Very Small Embryonic-like Stem Cells for Facial Skin Antiaging · Phase 1, PHASE2 · withdrawn
- NCT03975101 — Very Small Embryonic-like Stem Cells for Knee Osteoarthritis · Phase 1, PHASE2 · withdrawn
- NCT03985462 — Very Small Embryonic-like Stem Cells for Ovary · Phase 1, PHASE2 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT02857920 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fuda Cancer Hospital, Guangzhou
- Last refreshed: 14 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02857920.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing